Access Dermatology

Breaking News

• Home »
• Breaking News »
• Breaking News article

Use of alefacept for the treatment of psoriasis in Canada

A multicenter Canadian phase IV study --Amevive Wisdom Acquired From Real world Evidence (AWARE)-- is being conducted in psoriasis patients treated with alefacept. The study aims are to develop a national database to optimize the care of alefacept-treated patients, generate hypotheses for future research and determine how alefacept is used in a real-world clinical setting. Data recorded include body surface area (BSA) affected by psoriasis, alefacept dosing and time to retreatment, physician's global response (PGR), patient global response, concomitant psoriasis therapies and serious adverse events. To date (as of January 3, 2008), 426 patients have been enrolled. Preliminary data are available on 190 patients. At 18 weeks, alefacept effected a decrease in ...